Satraplatin FDA Approval Status
FDA Approved: No
Generic name: Satraplatin
Company: GPC Biotech AG
Treatment for: Prostate Cancer
Satraplatin is an investigational platinum-based drug for the second-line treatment of hormone refractory prostate cancer.
In July 2007, GPC Biotech AG announced the withdrawal of the New Drug Application (NDA) for satraplatin.
Development Timeline for Satraplatin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.